Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.

Zacks Investment Research • Feb 19, 2026

Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now

Over the past three years, healthcare has been among the worst-performing sectors. 2026's market rotation away from tech is bringing new life to more defensive areas of the market.

The Motley Fool • Feb 11, 2026

Biotech ETF (XBI) Hits New 52-Week High

XBI surges to a 52-week high, nearly doubling from its low, fueled by biotech momentum, AI adoption and easing macro trends.

Zacks Investment Research • Jan 23, 2026

Funding for Risky Biotechs Is Returning

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.

WSJ • Jan 12, 2026

Equities Surge, Commodities Sink As ETF Investors Streamline Portfolio For 2026

ETF investors are entering the new year with confidence, but not without caution.

Benzinga • Jan 6, 2026

Why 2026 may be a strong year for biotech stocks

Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid-cap biotech names – posting one of its strongest stretches on record. Mizuho's senior healthcare analyst Jared Holz believes this momentum is more than a short-term bounce.

Invezz • Dec 31, 2025

Mizuho's Jared Holz on what biotech dealmaking looks like in 2026

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.

CNBC Television • Dec 31, 2025

Mizuho's Jared Holz on why he is bullish on biotech heading into 2026

Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.

CNBC Television • Dec 24, 2025

Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus

The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.

Benzinga • Dec 23, 2025

Final Trades: Toast, Uber, the XLB and the XBI

The Investment Committee reveals the stocks they're watching as the market sets up for its next move.

CNBC Television • Dec 22, 2025